GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Short Interest

Valerio Therapeutics (FRA:C4X) Short Interest


View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Valerio Therapeutics's Short Interest

For the Biotechnology subindustry, Valerio Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Short Interest falls into.


Valerio Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Short Interest
Comparable Companies
XPAR:ALDVI XPAR:ALCOX XPAR:ALPAT XPAR:PHXM XPAR:ALACT XPAR:ALTME XPAR:ALNFL XPAR:ALTHX XPAR:ALTAO XPAR:ALINT OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX
Traded in Other Exchanges
ALVIO:France
Address
49 Boulevard du General, Martial Valin, Paris, FRA, 75015
Website
https://www.valeriotx.com
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics Headlines

No Headlines